# EXAM (NCT00704730)

> Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

No report yet. It can be ordered.

- Drugs tested: cabozantinib
- Indication: unresectable, locally advanced or metastatic medullary thyroid cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00704730
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Exelixis
- Conditions: Thyroid Cancer
- Interventions: XL184; Placebo
- Enrollment: 330
- Primary outcome: Progression-Free Survival (PFS)

## Indexed commentary on EXAM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=exam-nct00704730